BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Pharm Country

  J&J’s Daratumumab Proves Effective in Yet Another Multiple Myeloma Indication

  The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.

  October 22, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  RA Capital Closes $461 Million Investment Fund Aimed at Life Sciences Companies

  The new fund, RA Capital Nexus Fund II, will serve as a companion fund to RA’s Nexus I fund, which closed last year with approximately $300 million in capital.

  October 22, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Be Biopharma, AavantiBio Launch With Millions in Financing to Support Therapeutic Goals

  It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.

  October 22, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  BioSpace Movers & Shakers, Oct. 23

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  October 22, 2020

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  Moderna Fully Enrolls 30,000-Person COVID-19 Vaccine Trial, Boosts Minority Participation

  Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.

  October 22, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  Hope for Primary Hyperoxaluria: Alnylam Shares Positive Trial Results of Lumasiran

  Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.

  October 22, 2020

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Genetown

  Research Roundup: Predicting COVID-19 Cytokine Storm and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  October 22, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Researcher, CEO, Mentor – The Role of a Principal Investigator, Explained

  Are you passionate about research, business, science and leadership? If so, you might be interested in a job as a principal investigator.

  October 22, 2020

   · 

  5 min read

   · 

  Porschia Parker-Griffin
• 

  Career Advice

  The Top 5 Thing to Do (or Not Do) During a Zoom Interview

  Let’s take a closer look at a few things that you should definitely do, as well as a couple that you shouldn’t, in order to make a good first impression.

  October 22, 2020

   · 

  4 min read

   · 

  Kymberlie Krieger
• 

  FDA

  FDA Grants Full Approval to Remdesivir for COVID-19

  Shares of Gilead Sciences are jumping in aftermarket trading following full approval for Veklury (remdesivir) as a treatment for COVID-19. The approval marks the first drug approved by the U.S. Food and Drug Administration as a treatment for the novel coronavirus.

  October 22, 2020

   · 

  3 min read

   · 

  Alex Keown